The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction

Abstract Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint-driven clinical trials in patients with chronic kidney disease and type 2 diabetes mellitus (FIDELIO-DKD a...

Full description

Bibliographic Details

Published in:	Cardiovascular Diabetology
Main Authors:	Ulrich Kintscher, Frank Edelmann
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Subjects:	steroidal/ non-steroidal mineralocorticoid receptor antagonist Heart failure with preserved ejection fraction Finerenone Cardiac fibrosis Diastolic dysfunction
Online Access:	https://doi.org/10.1186/s12933-023-01899-0